Australia's Invion enters ophthalmology agreement with Sangmyung Innovation
19/05/2026 05:53
** Shares of Invion IVX.AX rise as much as 41.2% to A$0.072, their highest level since March 31 ** Life science co enters partnership with SANGMYUNG Innovation (SANGMYUNG), a South Korean therapeutic solutions company for eye-related diseases ** SANGMYUNG will fund and evaluate the Photosoft platform technology, Invion's photodynamic therapy (PDT), for the treatment of retinal vascular diseases ** About 3.3 million shares change hands, 23.4x 30-day average ** Stock down 43% this year, including the day's move (Reporting by Sherin Sunny in Bengaluru) ((Sherin.Sunny@thomsonreuters.com))
Recent news on Invion
See all newsAustralia's Invion rises after securing clinical trial funding arrangements
Brief: Invion Ltd Says Funding Agreements Cover Up To 85% Of Clinical Trials Costs
Brief: Invion Announces Preclinical Research Collaboration With Percheron Therapeutics
Australia's Invion enters ophthalmology agreement with Sangmyung Innovation
Brief: Invion Signs First Ophthalmology Collaboration Agreement With Sangmyung Innovation